by In2Pharma | Jun 22, 2022 | News
Belgium The Vigilance Division of the FAMHP requests marketing authorisation holders to send the approved version of the risk management plan for medicinal products for human use with a national marketing authorisation.In order to have a better overview of the...
by In2Pharma | Apr 9, 2019 | News
Belgium The FAMHP Vigilance department has found several encoding errors in the Article 57 database of the EMA. Some medicines licensed in Belgium appear two or three times in the database, in two or three national languages. As a result, they are registered multiple...
by In2Pharma | Feb 28, 2019 | News
European Union In light of the withdrawal of the United Kingdom from the European Union, the European Commission has published a letter on the rules for batch testing of medicinal products after the Brexit. The competent authorities may allow marketing authorisation...